A solid-phase radioimmunoassay for human prostatic acid phosphatase.
A solid-phase technique for radioimmunoassay of human prostatic acid phosphatase (EC 3.1.3.2) is described. Human prostatic acid phosphatase was purified from prostatic fluid. Monospecific antisera to the purified acid phosphatase were produced in rabbits. Disposable polypropylene tubes were coated with antiserum and used for radioimmunoassay with 125I-acid phosphatase. The nonspecific binding was minimized by saturating the binding sites of the tubes with bovine serum albumin. The working range of the technique was 1 to 30 ng of antigen. The solid-phase radioimmunoassay is rapid, sensitive, and efficient. In preliminary clinical trials it was shown that (a) patients with advanced prostatic cancer had elevated prostatic acid phosphatase levels by both enzymatic assay and radioimmunoassay assays, and (b) patients with other cancers were in the normal range for prostatic acid phosphatase.
D000135:Acid Phosphatase / Q000032:analysis*; D000818:Animals; D000918:Antibody Specificity; D006801:Humans; D007106:Immune Sera; D007457:Iodine Radioisotopes; D008297:Male; D011467:Prostate / Q000032:analysis* / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000201:enzymology; D011817:Rabbits / Q000276:immunology; D011863:Radioimmunoassay / Q000379:methods*; D013696:Temperature; D013997:Time Factors
D007106:Immune Sera; D007457:Iodine Radioisotopes; D000135:Acid Phosphatase